Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

Hrk024 Apr. 11 at 1:29 PM

$CING We did not get a "Granted" patent yet, we got a "Notice of Allowance." IMO, this is where buy out talks begin! Forget $12/share, I'm thinking $20/share in a blink minimum. CING is brewing a wonderful PR statement any day now with news of a granted US patent as well as being on track to hit the market end of May. FDA had questions on how the pill is "manufactured", nothing about the pill design itself, thank god. Allow them time to get the patent actually granted and share news that FDA's questions, NOT concerns, have been addressed. We will fly pass $12 a share.

1 · Reply

CARTE_BLANCHE_DEVEREAUX Apr. 10 at 10:45 PM

$IOVA $REPL $PYPD $CING REPL was obvious, although I feel for the longs here... As they (rightly) believe their drug works... Them and the OTLK people share the same pain. I love IOVA long term... But I'll be happy with 4/5x But PYPD and CING are the two most obvious 10 baggers (and more) from here.

3 · Reply

55X_ROI_Q1_2026 Apr. 10 at 10:05 PM

$CING I was here back at $11 ish saying it was DUMP on the News ... Buying Rumor of the Patent / sell the news, - it happened - and isn't the PDUFA also going to be Sell the News Event?

2 · Reply

alfi79 Apr. 10 at 9:03 PM

$CING

0 · Reply

isthisonebetter Apr. 10 at 8:39 PM

$CING

0 · Reply

BMWLTWM3 Apr. 10 at 8:12 PM

$CING returning to $11+ seems like a dream now instead of reality.... Good weekend all

0 · Reply

fullobullz Apr. 10 at 5:18 PM

$CING @alfi79 I usually just block the tall idiots.

0 · Reply

alfi79 Apr. 10 at 4:23 PM

$CING There are a lot of short idiots to block here...

0 · Reply

fullobullz Apr. 10 at 3:43 PM

$CING $REPL just litterally got destroyed from crl. Ouch!

2 · Reply

Duke1979 Apr. 10 at 2:57 PM

$CING so many people with opinions on stock price and timelines. Unless you are flipping dollars here, just get in and hold for the patent and FDA approval news. It doesn’t make sense to try to time it with news coming. IMO

0 · Reply

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Mar 16, 2026, 1:26 PM EDT - 26 days ago

Why did Cingulate stock skyrocket today?

Nov 18, 2025, 4:27 PM EST - 5 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Oct 23, 2025, 4:45 PM EDT - 6 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Sep 17, 2025, 8:45 AM EDT - 7 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Aug 21, 2025, 4:35 PM EDT - 8 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 8 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 8 months ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 8 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 10 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 1 year ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 2 years ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 2 years ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 3 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 3 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Hrk024 Apr. 11 at 1:29 PM

1 · Reply

CARTE_BLANCHE_DEVEREAUX Apr. 10 at 10:45 PM

3 · Reply

55X_ROI_Q1_2026 Apr. 10 at 10:05 PM

$CING I was here back at $11 ish saying it was DUMP on the News ... Buying Rumor of the Patent / sell the news, - it happened - and isn't the PDUFA also going to be Sell the News Event?

2 · Reply

alfi79 Apr. 10 at 9:03 PM

$CING

0 · Reply

isthisonebetter Apr. 10 at 8:39 PM

$CING

0 · Reply

BMWLTWM3 Apr. 10 at 8:12 PM

$CING returning to $11+ seems like a dream now instead of reality.... Good weekend all

0 · Reply

fullobullz Apr. 10 at 5:18 PM

$CING @alfi79 I usually just block the tall idiots.

0 · Reply

alfi79 Apr. 10 at 4:23 PM

$CING There are a lot of short idiots to block here...

0 · Reply

fullobullz Apr. 10 at 3:43 PM

$CING $REPL just litterally got destroyed from crl. Ouch!

2 · Reply

Duke1979 Apr. 10 at 2:57 PM

0 · Reply

ezimon Apr. 10 at 2:50 PM

$CING boss I do not know much about this stock, but for sure you post a lot of crap and you keep repeating it, do you believe that the rest of us if we read the same crap in a different format would makes us believe it?

0 · Reply

hossam94 Apr. 10 at 1:44 PM

$CING when we will start to move up , here ?!

0 · Reply

Stockeye2 Apr. 10 at 8:49 AM

$CING 👀🧐

0 · Reply

I_Buy_Stock Apr. 10 at 2:36 AM

$CING When, not if ladies and gents. pdufa date extension happens you gonna be able to accumulate at levels you could only dream of. I hope not, but if so who cares, it is inevitable.

3 · Reply

Kgra Apr. 10 at 1:03 AM

$CING that’s considered material if they have been notified by fda and they have 4 days to disclose …… if not we will know you are a liar and scumbag

0 · Reply

pitkineagle Apr. 10 at 12:11 AM

$CING I am happy you moved the date up from Nov. 11th that you posted on 3/19/26 as the PDUFA date. That’s two months less time to wait. Maybe you’ll change your mind again 😂😂🤣

0 · Reply

DonnyDarko11 Apr. 9 at 9:55 PM

$CING $TPST @bigdawg296 Mark my post! Insider just called. Looks like the manufacturing issue was with the thickness of the walls of each level of the pill. The FDA is making them run new batches. Estimates are 10 weeks to make batches to test, but then, on top of that, testing will take weeks. DELAY IN PUFDA! 9/1 will be new date. Sub $4 here we come!

2 · Reply

alfi79 Apr. 9 at 7:45 PM

$CING solid base here...ready for the next launch🚀

0 · Reply

DonnyDarko11 Apr. 9 at 3:31 PM

$CING Opening up big Short Position once Patent news hits. Will ride this all the way back down to $4 🤑. New PUFDA date of 9/1

4 · Reply

PaulWalter Apr. 9 at 3:29 PM

$CING Hope we’ve found a bottom.

0 · Reply

isthisonebetter Apr. 9 at 3:22 PM

$CING ok I’m in

0 · Reply

History101 Apr. 9 at 3:15 PM

$CING currently adding every dip below $6. GLTALs!!

0 · Reply

Market Cap	69.31M
Revenue (ttm)	0.00
Net Income (ttm)	-22.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.46

Volume	300,200
Avg Vol	499,040
Day's Range	N/A - N/A
Shares Out	11.63M
Stochastic %K	12%
Beta	-0.76
Analysts	Strong Sell
Price Target	$26.40